Volume 25, Issue 1 (Spring 2021)                   2021, 25(1): 19-24 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Esmaeili M H, Sofiabadi M, Afshar A. The Effects of Prenatal Norharman Exposure on Seizure Severity in Rats. Journal of Inflammatory Diseases. 2021; 25 (1) :19-24
URL: http://journal.qums.ac.ir/article-1-3149-en.html
1- Department of Physiology, Faculty of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.
2- Department of Physiology, Faculty of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran. , mohasofi@yahoo.com
Abstract:   (1975 Views)
Background: Norhraman is an alkaloid that can damage the nervous system.
Objective: This experimental study aimed to investigate the effects of prenatal norharman exposure on seizure severity in adult rats.
Methods: A total of 36 Wistar rats were randomly divided into 3 groups as follows: Control, sham (solvent), and norharman (1000 ug/kg). The sham and norharman groups were treated once daily for 8-18 of the fetal period. 2 months after birth, kindling was performed by the daily injection of Pentylenetetrazol (PTZ) (30 mg/kg); then, the seizure behavior was recorded for approximately 30 minutes. The obtained data were analyzed using Analysis of Variance (ANOVA) and Tukey’s posthoc test.
Results: The present study data indicated that administrating norharman in the fetal period increased seizure responses to PTZ, i.e., significant in the examined female rats (P<0.05).
Conclusion: According to the current research findings, the severity of seizures increases in subjects who have been exposed to norharman during the prenatal period.
Full-Text [PDF 726 kb]   (371 Downloads) |   |   Full-Text (HTML)  (263 Views)  
Type of Study: Research | Subject: Physiology

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Journal of Inflammatory Diseases

Designed & Developed by : Yektaweb